Gland Pharma Limited IPO: Issue Price, Listing Gain and Share Price Now
Gland Pharma Limited listed on 20-Nov-2020 at ₹1,820.45 against an issue price of ₹1,500 , a listing gain of +21.36%. It last traded at ₹2,823.55. This page is the record of that issue and what has happened to it since — reported figures only.
Gland Pharma Limited IPO: listing gain and return since
| Measure | Value |
|---|---|
| Issue price | ₹1,500 |
| Listing price (listing-day close) | ₹1,820.45 |
| Listing gain | +21.36% |
| Price now | ₹2,823.55 |
| Change from issue price | +88.24% |
| Change from listing-day close | +55.10% |
The two changes above answer different questions and are routinely opposite in sign. The change from the issue price is what an allottee has made. The change from the listing-day close is what somebody who bought on the first day has made.
Gland Pharma Limited IPO details
| Issue term | Detail |
|---|---|
| Issue price (upper band) | ₹1,500 |
| Issue size | ₹6,479.55 Cr |
| Fresh issue | ₹1,250 Cr |
| Offer for sale | ₹5,229.55 Cr |
| Issue opened | 09-Nov-2020 |
| Issue closed | 11-Nov-2020 |
| Listed on | 20-Nov-2020 |
| Exchange | BSE, NSE |
| Segment | Mainboard |
| Lead managers | Citigroup Global (left lead) |
How the Gland Pharma Limited IPO was subscribed
| Category | Subscription |
|---|---|
| QIB | 6.40x |
| NII | 0.51x |
| Retail | 0.24x |
| Total | 2.06x |
Gland Pharma Limited today
| Figure | Value |
|---|---|
| Market capitalisation | ₹46,521 Cr |
| Trailing P/E | 40.60x |
| Return on capital employed | 15.1% |
| Return on equity | 10.7% |
| 52-week high | ₹3,040 |
| 52-week low | ₹1,574 |
| Sector | Pharmaceuticals |
Fundamentals are as of the desk's last harvest and move with the market.
- Gland Pharma Limited — full issue page: every stored figure, with its source.
- How many IPOs still trade above their issue price, corporate-action adjusted.
- The full IPO archive: listing gains by year, sector and issue size.
Automated data digest. This page is compiled automatically from exchange filings and public aggregator data. It is a record of reported figures — it is not research, not a recommendation, and not investment advice.
Grey Market Premium (GMP) is an unofficial, unregulated price quoted outside the exchanges. It is not a forecast of the listing price and is frequently wrong.
Published by INVESTOLOGY — SEBI Registered Research Analyst INH000015297. Investments in securities markets are subject to market risk; read all offer documents carefully before investing. Registration granted by SEBI and NISM certification in no way guarantee performance or assure returns.